GJEPC innovNXT I Forty Under 40 - Next Gen Leadership Summit Witnesses Young Leaders Transforming The Business Landscape and Driving Growth-TBO TEK LIMITED IPO OPENS ON 8 May, 2024 PRICE BAND SET AT Rs. 875 TO 920 PER EQUITY SHARE-आधार हाउसिंग फाइनैंस लिमिटेड का आईपीओ 8-10 मई तक, 3,000 करोड़ जुटाएगी-Airbnb introduces Icons— Bollywood Star Jahnvi Kapoor opens the door to her legendary, never-before-seen family home in Chennai-AADHAR HOUSING FINANCE LIMITED IPO OPENS ON MAY 8, 2024 PRICE BAND SET AT Rs. 300 TO 315 PER EQUITY SHARE-महाराष्ट्र दिवस पर कालबादेवी में ओशो समारोह 'ओशो के अनुज डॉक्टर स्वामी शैलेंद्र सरस्वती' और 'मां अमृत प्रियाजी' की उपस्थिति में ओशो का ध्यान प्रयोग और प्रवचन होगा-Dr L H Hiranandani Hospital Launches Advanced Robotic System for Knee Replacement Surgeries-OSHO Meditation and Discourse to be hosted on 1st May at Sojat Swarna Bhawan, Kalbadevi, Mumbai In the gracious presence of Dr. Swami Shailendra Saraswati (OSHO’S Anuj) and Maa Amrut Priya-Lilavati Kirtilal Mehta Medical Trust Board Has Exposed A Major Financial Fraud Amounting Around Rs. 500 Crores, Making It A Serious Medical Scam-REC Announces Q4FY24 and 12M FY24 Results Net profit grows 33% to Rs 4,079 crore

LANXESS Q3 sales up 38.2% at EUR 2.185 billion

LANXESS HEADQUARTERS: Since August 1, 2013, Specialty Chemicals Group LANXESS is steering its global business from the LANXESS Tower in Cologne.

Lanxess Logo

EBITDA pre exceptionals increase 4.8 percent to EUR 240 million

MUMBAI, NOVEMBER 16, 2022 (GPN)– In a challenging environment with a continued rise in energy and raw material costs, the specialty chemicals company LANXESS delivered good results for the third quarter of 2022: Sales increased by a significant 38.2 percent from EUR 1.581 billion in the prior-year quarter to EUR 2.185 billion. EBITDA pre exceptionals reached EUR 240 million, growing by 4.8 percent compared to the previous year’s figure of EUR 229 million.

The good figures show that our strategy is taking us in the right direction. In turbulent times, we are much more stable than before thanks to our focus on less cyclical specialty chemicals. Midway through the year, we strengthened our Consumer Protection segment again by acquiring the Microbial Control business from IFF, and this has already paid off in the past quarter,” said Matthias Zachert, Chairman of the Board of Management of LANXESS AG. “However, we have already seen waning demand in some areas and an overall decline in the volume sold. In the fourth quarter, the headwind will blow even stronger due to further rises in energy prices and the threat of recession.”

LANXESS has specified its guidance for the full fiscal year 2022. The Group expects net income of between EUR 900 million and EUR 950 million, which would thus be well above the adjusted prior-year level of EUR 815 million. Previously, the Group anticipated EBITDA pre exceptionals of between EUR 900 million and EUR 1 billion.

Net income from continuing operations amounted to EUR 84 million in the third quarter, compared with EUR 40 million in the prior-year period.

In addition to the Additives businesses the development in the Consumer Protection segment, which the Group has strategically built up in recent years, was particularly positive. The Microbial Control business acquired from the U.S. corporation International Flavors & Fragrances (IFF) as of July 1, 2022, has already made a significant contribution to the segment’s good earnings as well as the businesses of Emerald Kalama Chemical acquired in 2021. LANXESS passed on the further increase in energy and raw material costs via higher selling prices. Exchange rates also had a positive effect on earnings in all segments, while demand weakened in some customer industries such as construction. The EBITDA margin pre exceptionals decreased to 11.0 percent in the third quarter, against 14.5 percent in the prior-year quarter.

€ million   Q3 2021   Q3 2022   Change %   9M 2021   9M 2022   Change %
                         
Sales   1,581   2,185   38.2   4,422   6,115   38.3
EBITDA pre exceptionals   229   240   4.8   643   755   17.4
EBITDA margin pre exceptionals   14.5%   11.0%       14.5%   12.3%    
Net income   74   80   8.1   238   271   13.9
from continuing operations   40   84   > 100   123   198   61.1
from discontinued operations   34   -4   < -100   115   73   -36.5

                                                                          

About the Author

Sachin Murdeshwar
Sachin Murdeshwar is a Sr.Journalist and Columnist in several Mainline Newspapers and Portals.He is an ardent traveller and likes to explore destinations to the core.

Be the first to comment on "LANXESS Q3 sales up 38.2% at EUR 2.185 billion"

Leave a comment

Your email address will not be published.


*